Leroy M. Parker

4.6k total citations · 1 hit paper
39 papers, 2.6k citations indexed

About

Leroy M. Parker is a scholar working on Oncology, Cancer Research and Immunology. According to data from OpenAlex, Leroy M. Parker has authored 39 papers receiving a total of 2.6k indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Oncology, 8 papers in Cancer Research and 7 papers in Immunology. Recurrent topics in Leroy M. Parker's work include Cancer Treatment and Pharmacology (11 papers), Breast Cancer Treatment Studies (7 papers) and HER2/EGFR in Cancer Research (6 papers). Leroy M. Parker is often cited by papers focused on Cancer Treatment and Pharmacology (11 papers), Breast Cancer Treatment Studies (7 papers) and HER2/EGFR in Cancer Research (6 papers). Leroy M. Parker collaborates with scholars based in United States, Norway and Austria. Leroy M. Parker's co-authors include C. Thomas Griffiths, Eric P. Winer, Harold J. Burstein, James G. Rheinwald, Ying-Jye Wu, John H. Sinard, Michael A. Beckett, Alfred D. Steinberg, Jerry Younger and Craig A. Bunnell and has published in prestigious journals such as New England Journal of Medicine, Cell and Journal of Clinical Oncology.

In The Last Decade

Leroy M. Parker

39 papers receiving 2.5k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

The mesothelial keratins: A new family of cytoskeletal proteins identified in cultured mesothelial cells and nonkeratinizing epithelia

1982 475 citations Leroy M. Parker, C. Thomas Griffiths et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Leroy M. Parker United States	24	1.2k	517	475	390	379	39	2.6k
Richard S. Camplejohn United Kingdom	26	1.1k 0.9×	1.0k 2.0×	582 1.2×	736 1.9×	239 0.6×	62	3.1k
Jean Michel Foidart Belgium	32	1.3k 1.1×	1.2k 2.3×	936 2.0×	266 0.7×	301 0.8×	70	4.1k
Miguel Á. Idoate Spain	28	1.1k 0.9×	809 1.6×	458 1.0×	690 1.8×	193 0.5×	146	3.2k
Kouki Inai Japan	32	868 0.7×	1.2k 2.3×	457 1.0×	1.0k 2.6×	175 0.5×	104	3.1k
Wolfgang Oster Germany	28	760 0.6×	674 1.3×	197 0.4×	546 1.4×	489 1.3×	101	3.0k
Aurelio Ariza Spain	31	990 0.8×	902 1.7×	252 0.5×	1.1k 2.8×	178 0.5×	93	3.5k
Gero Brockhoff Germany	32	1.5k 1.2×	1.2k 2.4×	491 1.0×	302 0.8×	478 1.3×	113	3.5k
Yoshiyuki Abe Japan	29	1.0k 0.8×	1.4k 2.7×	741 1.6×	512 1.3×	389 1.0×	137	2.9k
G R Mundy United States	26	2.2k 1.8×	2.1k 4.0×	284 0.6×	371 1.0×	363 1.0×	51	3.8k
Torahiko Nakashima Japan	28	1.2k 1.0×	890 1.7×	300 0.6×	414 1.1×	331 0.9×	140	3.0k

Countries citing papers authored by Leroy M. Parker

Since Specialization

Citations

This map shows the geographic impact of Leroy M. Parker's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Leroy M. Parker with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Leroy M. Parker more than expected).

Fields of papers citing papers by Leroy M. Parker

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Leroy M. Parker. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Leroy M. Parker. The network helps show where Leroy M. Parker may publish in the future.

Co-authorship network of co-authors of Leroy M. Parker

This figure shows the co-authorship network connecting the top 25 collaborators of Leroy M. Parker. A scholar is included among the top collaborators of Leroy M. Parker based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Leroy M. Parker. Leroy M. Parker is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Mayer, Erica L., Lyndsay N. Harris, Julie Gold, et al.. (2014). Long-Term Follow-Up After Preoperative Trastuzumab and Chemotherapy for HER2-Overexpressing Breast Cancer. Clinical Breast Cancer. 15(1). 24–30. 11 indexed citations

Chen, Wendy Y., Anita Giobbie‐Hurder, Jennifer Savoie, et al.. (2014). A randomized, placebo-controlled trial of melatonin on breast cancer survivors: impact on sleep, mood, and hot flashes. Breast Cancer Research and Treatment. 145(2). 381–388. 96 indexed citations

Campos, Susana M., Suzanne Berlin, Leroy M. Parker, et al.. (2010). Phase I trial of liposomal doxorubicin and ZD1839 in patients with refractory gynecological malignancies or metastatic breast cancer. International Journal of Clinical Oncology. 15(4). 390–398. 4 indexed citations

Snyder, Brian D., Ara Nazarian, David J. Chang, et al.. (2009). Noninvasive Prediction of Fracture Risk in Patients with Metastatic Cancer to the Spine. Clinical Cancer Research. 15(24). 7676–7683. 56 indexed citations

Lin, Nancy U., Leroy M. Parker, Steven E. Come, et al.. (2007). Phase II study of CT-2103 as first- or second-line chemotherapy in patients with metastatic breast cancer: unexpected incidence of hypersensitivity reactions. Investigational New Drugs. 25(4). 369–375. 28 indexed citations

Burstein, Harold J., Leroy M. Parker, Aparna Keshaviah, et al.. (2005). Efficacy of Pegfilgrastim and Darbepoetin Alfa As Hematopoietic Support for Dose-Dense Every-2-Week Adjuvant Breast Cancer Chemotherapy. Journal of Clinical Oncology. 23(33). 8340–8347. 43 indexed citations

Burstein, Harold J., Jennifer R. Bellon, Sharon Galper, et al.. (2005). Prospective evaluation of concurrent paclitaxel and radiation therapy after adjuvant doxorubicin and cyclophosphamide chemotherapy for Stage II or III breast cancer. International Journal of Radiation Oncology*Biology*Physics. 64(2). 496–504. 39 indexed citations

Robertson, J.F.R., Björn Erikstein, Kent C. Osborne, et al.. (2004). Pharmacokinetic Profile of Intramuscular Fulvestrant in Advanced Breast Cancer. Clinical Pharmacokinetics. 43(8). 529–538. 71 indexed citations

Burstein, Harold J., Lyndsay N. Harris, Rebecca Gelman, et al.. (2002). Preoperative Therapy With Trastuzumab and Paclitaxel Followed by Sequential Adjuvant Doxorubicin/Cyclophosphamide for HER2 Overexpressing Stage II or III Breast Cancer: A Pilot Study. Journal of Clinical Oncology. 21(1). 46–53. 221 indexed citations

10.

Burstein, Harold J., Irene Kuter, Susana M. Campos, et al.. (2001). Clinical Activity of Trastuzumab and Vinorelbine in Women With HER2-Overexpressing Metastatic Breast Cancer. Journal of Clinical Oncology. 19(10). 2722–2730. 290 indexed citations

11.

Hillyer, Christopher D., Raymond L. Comenzo, Kenneth B. Miller, et al.. (1991). Prompt engraftment using autologous peripheral blood stem cells for double autologous bone marrow rescue. American Journal of Hematology. 36(2). 152–153. 4 indexed citations

12.

Lamb, Carolyn C., et al.. (1991). Results of radical radiotherapy for inflammatory breast cancer. The American Journal of Surgery. 162(3). 236–242. 18 indexed citations

13.

Sheldon, Thomas A., Daniel F. Hayes, Blake Cady, et al.. (1987). Primary radiation therapy for locally advanced breast cancer. Cancer. 60(6). 1219–1225. 49 indexed citations

14.

Berek, Jonathan S., Robert C. Knapp, Neville F. Hacker, et al.. (1985). Intraperitoneal immunotherapy of epithelial ovarian carcinoma with Corynebacterium parvum. American Journal of Obstetrics and Gynecology. 152(8). 1003–1010. 29 indexed citations

15.

Bast, Robert C., Thomas L. Klug, Eric L. Jenison, et al.. (1984). A Radioimmunoassay Using a Monoclonal Antibody To Monitor the Course of Epithelial Ovarian Cancer. Obstetrical & Gynecological Survey. 39(3). 169–170. 83 indexed citations

16.

Parker, Leroy M., et al.. (1981). PROLONGED CRYOPRESERVATION OF HUMAN BONE MARROW. Transplantation. 31(6). 454–457. 22 indexed citations

17.

Frei, E, Ronald H. Blum, Susan W. Pitman, et al.. (1980). High dose methotrexate with leucovorin rescue. The American Journal of Medicine. 68(3). 370–376. 128 indexed citations

18.

Parker, Leroy M., C. Thomas Griffiths, Ronald A. Yankee, et al.. (1980). Combination chemotherapy with adriamycin-cyclophosphamide for advanced ovarian carcinoma. Cancer. 46(4). 669–674. 35 indexed citations

19.

Cotter, Susan M. & Leroy M. Parker. (1978). High-Dose Methotrexate and Leucovorin Rescue in Dogs with Osteogenic Sarcoma. American Journal of Veterinary Research. 39(12). 1943–1945. 7 indexed citations

20.

Tobias, Jeffrey, Roy S. Weiner, C. Thomas Griffiths, et al.. (1977). Cryopreserved autologous marrow infusion following high dose cancer chemotherapy. European Journal of Cancer (1965). 13(3). 269–277. 33 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact